A Hybrid Cost Model For Valuing Clinical Trials, Clinical Research, and Investigator-Sponsored Studies
FairClin™ is Fairmark’s proprietary database of FMV rates for clinical trials, clinical research, and investigator-initiated studies. FairClin™ covers major markets in the United States, Europe, Asia/Pacific, and the Americas; and includes rates for both the labor and non-labor components of research.
Fairmark uses a hybrid cost-based valuation methodology to determine Fair Market Value (FMV) for clinical research activities.
Clinical research activities often involve complex, non-routine tasks that differ substantially from standard medical practice, making pure market-based comparisons unreliable or unavailable. For this reason, our hybrid cost-based approach provides the most accurate, defensible, and study-specific valuation.
Our methodology identifies each discrete cost driver within the protocol or activity being evaluated, allowing FMV estimates to reflect the true time, effort, and resources required.
By focusing on actual inputs rather than generalized benchmarks, Fairmark’s hybrid cost-based model produces precise, transparent valuations aligned with the unique operational complexities of each study.
